title: Pseudohallucinations associated with moclobemide: a case report.
abstract: The goal of the multicenter drug surveillance project AMSP ("Arzneimittelsicherheit in der Psychiatrie") is the monitoring, assessment and analysis of adverse drug reactions (ADR) of psychopharmalogical drugs. We report about a 23 year-old patient with a depressive episode. He developed severe pseudohallucinations under a treatment with moclobemide. The symptoms occur 6 days after starting the medication and decline within two days after stopping moclobemide. The term "pseudohallucinations" is discussed controversially but still of high interest.
authors: Department of Psychiatry and Psychotherapy, Georg-August University of Göttingen, Germany. ddegner@gwdg.de
authors: D
authors: D
authors: Degner
authors: S
authors: S
authors: Kropp
authors: J
authors: J
authors: Porzig
authors: R
authors: R
authors: Grohmann
authors: E
authors: E
authors: Rüther
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D006212:Hallucinations / Q000139:chemically induced* / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078785:Mirtazapine; D020912:Moclobemide / Q000009:adverse effects* / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D020280:Sertraline / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D008803:Mianserin; D000078785:Mirtazapine; D020912:Moclobemide; D020280:Sertraline